| Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy. | |
| | |
MedLine Citation:
|
PMID: 22302255 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Purpose A case of persistent hematologic abnormalities in a patient receiving long-term omalizumab therapy for severe asthma is reported. Summary During the course of her treatment at an asthma clinic, a 24-year-old woman was noted to have increased white blood cell counts, with elevated myeloid cell counts; the blood abnormalities were first documented more than 12 months previously. The woman had been taking omalizumab for more than 2 years and was also receiving immmune globulin therapy for common variable immunodeficiency. Based on the results of bone marrow aspiration and biopsy, she was diagnosed as having mild neutrophilia, possibly related to past corticosteroid therapy, but there was no evidence of a malignancy, a hemophagocytic syndrome, or an infectious, myeloproliferative, or lymphoproliferative process. Pursuant to a multidisciplinary medication review, the use of omalizumab was identified as a potential factor in the myeloid cell elevations and discontinued. About 1 month after omalizumab therapy was halted, the patient's myeloid cell counts normalized. The temporal association of omalizumab use and blood abnormalities in this case, coupled with the lack of data on the drug's long-term hematologic effects, suggests a need for cautious use and close monitoring of omalizumab therapy, particularly in younger patients. Conclusion A patient with asthma and common variable immunodeficiency developed an elevation of peripheral blood myeloid cells that was first noticed 29 months after the initiation of monthly omalizumab injections. Omalizumab was discontinued, and the abnormality persisted for 1 month after the last dose. The patient's blood count results remained within normal limits 3 months after the last dose. |
| | |
Authors:
|
Hoan Linh Banh; June Trevoy; Henry Pabst; Jeremy Beach; Dilini Vethanayagam |
Related Documents
:
|
1188105 - An extravascular component of contrast enhancement in cranial computed tomography. part... 16732615 - Microvascular system of anterior cruciate ligament in dogs. 22395355 - Use of blood products and risk of stroke after coronary artery bypass surgery. 21142975 - Performance of a new test strip for freestyle blood glucose monitoring systems. 2784665 - Apparent coagulopathy caused by infusion of shed mediastinal blood and its prevention b... 2964095 - Chromosome aberrations in mixed cultures of in vitro irradiated and unirradiated human ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 69 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-02-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 302-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Strategies to preserve the use of statins in patients with previous muscular adverse effects.
Next Document: Comparison of rates of reported adverse events associated with i.v. iron products in the United Stat...